Physician

Internal Medicine

Doctor Nathan M. Bass, MD works in the field of Internal Medicine. He received 1 awards: "Elected Member". Doctor Nathan M. Bass, MD is a published doctor as well. He has 43 publications published. The latest was: Rifaximin is Safe and Well Tolerated for Long-Term Maintenance of Remission From Overt Hepatic Encephalopathy.

Publications

---

• Rifaximin is Safe and Well Tolerated for Long-Term Maintenance of Remission From Overt Hepatic Encephalopathy.
• Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis.
• Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
• Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatoHepatitis: a pioglitazone versus vitamin E versus placebo for the trea...
• Association between diabetes, family history of diabetes and risk of nonalcoholic steatoHepatitis and fibrosis.
• Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent Hepatitis C virus.
• Centrizonal arteries and microvessels in nonalcoholic steatoHepatitis.
• SIRT3 Deficiency and Mitochondrial Protein Hyperacetylation Accelerate the Development of the Metabolic Syndrome.
• Emergent orthotopic liver transplantation for hemorrhage from a giant cavernous hepatic hemangioma: case report and review.
• Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.
• The treatment of hepatic encephalopathy in the cirrhotic patient.
• Rifaximin treatment in hepatic encephalopathy.
• Lipidomic dissection of nonalcoholic steatoHepatitis: moving beyond foie gras to fat traffic.
• Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation.
• Prediction of clinical outcomes in primary biliary Cirrhosis by serum enhanced liver fibrosis assay.
• Liver steatosis: investigation of opposed-phase T1-weighted liver MR signal intensity loss and visceral fat measurement as biomarkers.
• Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.
• A clinical scoring system for predicting nonalcoholic steatoHepatitis in morbidly obese patients.
• Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease.
• Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
• Amyloidosis localized to the liver.
• Safety and efficacy of TIPS in patients with hemophilia and Cirrhosis.
• Medical treatment of non-alcoholic steatoHepatitis.
• Abnormal liver function tests in the patient transplanted 3 years ago for alcoholic liver disease.
• Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.
• Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.
• Genetic influences in nonalcoholic fatty liver disease.
• A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.
• Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists.
• Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary Cirrhosis.
• Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease.
• Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related Cirrhosis.
• Serum sodium predicts mortality in patients listed for liver transplantation.
• Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha ac...
• Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
• Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores.
• CT signs of hepatofugal portal venous flow in patients with Cirrhosis.
• Primary sclerosing cholangitis.
• A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications f...
• Leukotriene antagonists.
• Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
• Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.

Schools

---

• University Of Cape Town Faculty Of Health Sciences

• Groote Schuur Hospital

• Royal Free Hospital

• University Calif San Francisco

Conditions Treated

---

• Anemia
• Cholecystitis and Gallstones
• Cirrhosis
• Hepatitis B - Immune Response

Doctors Specialties

---

• Gastroenterology
• Internal Medicine

Accepted Insurances

---

• Blue Card PPO
• Blue Cross Blue Shield of California PPO
• Cigna HMO
• First Health (Coventry Health Care) PPO

Awards

---

• Elected Member

Education

---

• University of Cape Town Faculty of Medicine

Hospital

---

• UCSF Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Priscilla G. Yee, MD This Doctor is OpenDoctor Recommended.
	Dr. Meenakshi Jain, MD This Doctor is OpenDoctor Recommended.
	Dr. Eric J. Smith, MD
	Dr. John V. Fahy, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jeffrey N. Siegel, MD
	Dr. Robert H. Gelber, MD
	Dr. Choon H. Goh, MD
	Dr. Derice P. Seid, MD
	Dr. Damian H. Augustyn, MD This Doctor is OpenDoctor Recommended.
	Dr. Joseph Chen, MD This Doctor is OpenDoctor Recommended.
	Dr. Chanda K. Ho, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog